Clinical Trial Update: Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial of ART-123 for acute exacerbation of idiopathic pulmonary fibrosis has completed, according to the trial registry update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• ART-123 (recombinant human soluble thrombomodulin)

Snippet

Sponsor: Asahi Kasei Therapeutics Corporation | Conditions: Idiopathic Pulmonary Fibrosis | Phase 3 | Status: COMPLETED